pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CAR-T · news · pharmadog
← back to CAR-T
News · CAR-T
124
stories
9h
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
9h
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
3d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
3d
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
fiercebiotech
3d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
4d
Trump administration appeals ruling blocking limits on international student visas
stat
5d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
6d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
Spark co-founder Steven Altschuler is back with an immune-resetting biotech
endpoints
6d
Adicet Bio shares promising look at CAR-T for lupus, but stock drops anyway
endpoints
6d
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
biopharma dive
6d
Scynexis' BARDA alliance; Bristol Myers' early data for dual-targeting CAR-T
endpoints
10d
Endpoints 11 2026 winner Azalea melds gene editing and CAR-T
endpoints
10d
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
10d
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
biospace
11d
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
11d
Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
endpoints
11d
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
fiercebiotech
12d
9 companies hiring in Pennsylvania now
biospace
17d
Cellares and Ori Biotech’s new cell therapy manufacturing contracts
endpoints
17d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
18d
Webinar: Manufacturing in Turbulent Times
biospace
19d
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
20d
Blood centers can help biopharma scale cell and gene therapies
biospace
20d
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
21d
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
21d
Unlocking cell surface protein research with site-specific labeling
biospace
24d
Novartis drags peers down with triple asset stumble
biospace
25d
STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
stat
25d
STAT+: Cancer medicines remain in short supply across the U.S., survey finds
stat
← prev
page 1 of 5
next →
